Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Commission (EC) has granted an orphan drug status to BioAlliance Pharma's clonidine Lauriad.
Subscribe to our email newsletter
The clonidine Lauriad is used to prevent radiotherapy-induced oral mucositis in patients with head and neck cancer.
BioAlliance Pharma COO Judith Greciet said the European designation for clonidine Lauriad as an orphan drug is key in shortening its development timeline, optimizing costs and reinforcing its future market access.